CALGB 40601: Randomized Phase III Trial of Paclitaxel Combined With Trastuzumab, Lapatinib, or Both As Neoadjuvant Treatment of HER2-Positive Primary Breast Cancer
Getting access
Committee review Health/Medical/Biomedical (COL) (HMB-COL)
- Apply at
- https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001570.v4.p1
- Agreement
- Data use agreement
- Cost
- No charge
- Renewal
- Every 1 year
From the operator’s published policy metadata.
About this database
| Last updated | 2026-09-12 |
|---|